drugset / Trial / NCT04068974
Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is intend to improve the progression-free survial of the recurrent paltinum-resistant ovarian cancer. All the participants will receive camrelizumab combined with apatinib.
Timeline
- Start
- 2019-10-28
- Primary completion
- 2021-06-30
- Completion
- 2022-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |
Indications
No indication recorded.